1223-Host Immune Dynamics After CAR T Therapy in GBM

This article examines the immune system's reaction to a specific cancer treatment known as intracerebroventricular CAR T cell therapy in patients with recurrent glioblastoma. Researchers utilized advanced single-cell RNA sequencing and spectral cytometry to observe how both the engineered cells and the patient's own endogenous immune compartment change after infusion. The study highlights that the presence of host immune cells in the cerebrospinal fluid significantly evolves following treatment, potentially influencing the therapy's overall success. Data collected from various patient cohorts and brain organoid models suggest that the tumor environment adapts to treatment through mesenchymal shifts and physical barriers. Ultimately, the findings emphasize the critical role of the natural immune response in supporting or resisting high-tech cellular interventions within the brain.References:Freeburg N F, Chafamo D, Gopikrishna G K, et al. The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM[J]. Cell, 2026.前往小宇宙评论区与主播互动